Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer

PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. EXPERIMENTAL DESIGN: The HR status of 12 OCCC cell lines was determined using RAD5...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Wilkerson, Paul M, Dedes, Konstantin J, Samartzis, Eleftherios Pierre, Dedes, Ioannis, Lambros, Maryou B, Natrajan, Rachael, Gauthier, Arnaud, Piscuoglio, Salvatore, Töpfer, Chantal, Vukovic, Vesna, Daley, Frances, Weigelt, Britta, Reis-Filho, Jorge S
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351612/
https://ncbi.nlm.nih.gov/pubmed/28002809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars